Barinthus Begin Period Cash Flow from 2010 to 2025
| BRNS Stock | 1.04 0.03 2.97% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 223.5 M | Current Value 234.7 M | Quarterly Volatility 84.9 M |
Check Barinthus Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Barinthus Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.6 M, Interest Expense of 23.9 K or Total Revenue of 876.2 K, as well as many indicators such as Price To Sales Ratio of 193, Dividend Yield of 0.0 or PTB Ratio of 0.54. Barinthus financial statements analysis is a perfect complement when working with Barinthus Biotherapeutics Valuation or Volatility modules.
Barinthus | Begin Period Cash Flow |
Latest Barinthus Biotherapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Barinthus Biotherapeutics plc over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Barinthus Biotherapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Barinthus Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Barinthus Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 75,252,115 | |
| Geometric Mean | 45,614,278 | |
| Coefficient Of Variation | 112.79 | |
| Mean Deviation | 70,711,647 | |
| Median | 28,263,421 | |
| Standard Deviation | 84,874,096 | |
| Sample Variance | 7203.6T | |
| Range | 223.3M | |
| R-Value | 0.76 | |
| Mean Square Error | 3315.4T | |
| R-Squared | 0.57 | |
| Significance | 0.0007 | |
| Slope | 13,464,400 | |
| Total Sum of Squares | 108054.2T |
Barinthus Begin Period Cash Flow History
About Barinthus Biotherapeutics Financial Statements
Barinthus Biotherapeutics shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Barinthus Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Barinthus Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Barinthus Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 223.5 M | 234.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.